Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase of Chronic Myeloid Leukemia Clinical Trial

Status Completed

Clinical Trial Summary

Interferon alpha was a therapy used in Chronic Myeloid Leukemia in Chronic phase prior to the advent of tyrosine kinase inhibitors. Synergistic effect of the combination of Peg-IFNα2a with Imatinib was demonstrated in the clinical SPIRIT trial. In this study, the investigators address the question of the efficacy and safety of dasatinib in combination with low dose of Peg-IFNα-2b as frontline therapy for patients with newly diagnosed Chronic Myeloid Leukemia in Chronic phase.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Chronic Phase of Chronic Myeloid Leukemia
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid

• NCT number: NCT01872442
• Study type: Interventional
• Source: Poitiers University Hospital
• Status: Completed
• Phase: Phase 2
• Start date: October 15, 2013
• Completion date: October 31, 2018